InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index
by is licensed under

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has been included in the CSE25 Index after qualifying as one of the 25 largest companies in the CSE Composite Index. Per the update, the CSE25 Index is a subgroup of the CSE Composite Index, which was launched in 2015 and currently includes nearly half of the exchange’s listed companies and over 75 percent of the trading activity on the Canadian Securities Exchange. The CSE25 Index includes the top 25 securities contained within the CSE Composite Index based on market capitalization. According to the exchange, CSE25 companies account for more than 50 percent of the weighting of the larger CSE Composite Index, meaning that the 25 included stocks typically attract “considerable trading volume.”

Read the full article

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Read More
Tags
Cannabis News, InMed
Thumbnail Photo Credit: by is licensed under